Pfizer (PFE) stock
Health Care · Pharmaceuticals
Pfizer (PFE) is a Pharmaceuticals company in the Health Care sector, headquartered in New York City, New York. As of October 23, 2026, PFE closed at $30.03, a market capitalization of $171.16 billion, the 73rd largest company in the S&P 500. Over the last twelve months it generated $63.70 billion in revenue (+3% year over year) and $10.98 billion in free cash flow. The stock trades at 39.5x trailing earnings and 10.4x forward earnings.
- 1-year total return: +30.3% (dividends reinvested)
- 5-year return: -1.9% a year
- 52-week range: $23.62 – $30.44
- Gross margin 74.7%, operating margin 27.9%
- Dividend yield: 5.73%, 16 straight years of increases
- FI Handbook report card: C+ across 10 metrics
- 10th largest of 60 Health Care stocks in the S&P 500
PFE price chart
1Y price change: +21.7% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| PFE | +6.6% | +26.8% | +30.3% | +5.7% | -1.9% | +4.5% | +10.4% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1972.
PFE key statistics
- Market cap
- $171.2B
- #73 in S&P 500
- P/E (TTM)
- 39.5x
- Forward P/E
- 10.4x
- EPS (TTM)
- $0.76
- Revenue (TTM)
- $63.7B
- +3%
- Free cash flow
- $11.0B
- Gross margin
- 74.7%
- Operating margin
- 27.9%
- Return on equity
- 5.0%
- Dividend yield
- 5.73%
- 52-week range
- $23.62 – $30.44
- Beta
- 0.28
- Price / sales
- 2.7x
- EV / EBITDA
- 8.8x
- Debt / equity
- 0.74x
- Employees
- 75,000
PFE report card
C+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth2.6%D
- Gross margin74.7%A
- Operating margin27.9%B
- FCF margin17.2%B
- Return on equity5.0%D
- Net debt / EBITDA2.0xD
- Forward P/E10.4xA
- PEG ratio12.8xF
- Shareholder yield5.7%A
- Share count change / yr0.3%C
Pfizer financials
Revenue went from $52.8B in fiscal 2016 to $62.6B in fiscal 2025, growing 1.9% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.8B | $52.5B | $40.8B | $40.9B | $41.7B | $73.6B | $91.8B | $50.9B | $63.6B | $62.6B |
| Gross profit | $40.5B | $41.3B | $31.8B | $32.9B | $33.2B | $42.8B | $57.4B | $26.0B | $45.8B | $46.5B |
| Net income | $7.2B | $21.3B | $11.2B | $16.0B | $9.2B | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B |
| EPS (diluted) | $1.11 | $3.34 | $1.87 | $2.82 | $1.63 | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 |
| Free cash flow | $14.4B | $14.8B | $13.8B | $10.5B | $12.2B | $29.9B | $26.0B | $4.8B | $9.8B | $9.1B |
| Buybacks | $5.0B | $5.0B | $12.2B | $8.9B | $0 | $0 | $2.0B | $0 | $0 | — |
| Diluted shares | 6.5B | 6.4B | 6.0B | 5.7B | 5.6B | 5.7B | 5.7B | 5.7B | 5.7B | 5.7B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into PFE?
A reverse DCF asks what growth the current price requires. With an enterprise value of $222.9B and $11.0B of trailing free cash flow, Pfizer needs to grow free cash flow about 10.9% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew -5.7% a year over the last five years.
P/E ratio history
Current 22.1x vs. median 17.3x (10th–90th percentile 10.1x–31.0x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
PFE dividend
- Dividend yield
- 5.73%
- Annual dividend
- $1.72
- Years of increases
- 16
- 5-yr dividend growth
- 3.6%
- per year
- Payout ratio
- 226%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
PFE earnings
Next report: November 3, 2026. Pfizer has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $15.0B (+3% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 4, 2026 | $0.68 | $0.77 | +12.9% |
| May 5, 2026 | $0.72 | $0.75 | +3.9% |
| Feb 3, 2026 | $0.57 | $0.66 | +16.2% |
| Nov 4, 2025 | $0.63 | $0.87 | +37.4% |
| Aug 5, 2025 | $0.57 | $0.78 | +35.9% |
| Apr 29, 2025 | $0.67 | $0.92 | +36.5% |
| Feb 4, 2025 | $0.46 | $0.63 | +37.2% |
| Oct 29, 2024 | $0.61 | $1.06 | +73.3% |
Stocks like PFE
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 BMY Bristol-Myers Squibb | -2.41% | +47% | $125.6B | 13.5x | Compare |
 ZTS Zoetis | -1.18% | -44% | $33.5B | 13.3x | Compare |
 VTRS Viatris | -2.60% | +81% | $20.7B | — | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
PFE news
- Pfizer And 2 Other AI Healthcare Stocks To Watch · Oct 24, 2026
- Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 · Oct 24, 2026
- Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem · Oct 24, 2026
- Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes? · Oct 24, 2026
- Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip · Oct 23, 2026
PFE stock FAQ
What is PFE's market cap?
Pfizer's market capitalization is $171.16 billion as of October 23, 2026, ranking 73rd in the S&P 500.
What is PFE's P/E ratio?
PFE trades at a trailing price-to-earnings ratio of 39.5x and a forward P/E of 10.4x. Its median P/E over the period we track is 17.3x.
Does PFE pay a dividend?
Yes. Pfizer pays $1.72 per share a year, a 5.73% yield. It has raised its dividend 16 years in a row. Dividends grew 3.6% a year over the last five years.
How much has PFE stock returned?
Including reinvested dividends, PFE returned +30.3% over one year, -1.9% a year over five years, +4.5% a year over ten years through October 23, 2026.
Is PFE stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Pfizer must grow free cash flow about 11% a year for the next decade. Its free cash flow fell 6% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
When does PFE report earnings?
Pfizer is expected to report earnings on November 3, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Pfizer have?
Pfizer has about 75,000 full-time employees, or $849,280 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology